Compare REGCP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REGCP | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.7M |
| IPO Year | 1994 | 2015 |
| Metric | REGCP | BRTX |
|---|---|---|
| Price | $23.00 | $2.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 212.3K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,553,524,000.00 | $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | $49.92 | ★ N/A |
| Revenue Growth | ★ 6.85 | N/A |
| 52 Week Low | $22.35 | $0.14 |
| 52 Week High | $24.74 | $4.10 |
| Indicator | REGCP | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 62.80 |
| Support Level | $22.97 | $0.22 |
| Resistance Level | $23.58 | $4.10 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 33.96 | 65.76 |
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.